SYS 6006
Alternative Names: SYS-6006Latest Information Update: 11 May 2022
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 09 May 2022 CSPC Pharmaceutical Group plans clinical trials in COVID-2019 infections (Prevention)
- 29 Apr 2022 Phase-I clinical trials in COVID-2019 infections (Prevention, In adults, In the elderly) in China (IM) (NCT05354063)
- 26 Apr 2022 Phase-I clinical trials in COVID-2019 infections (Prevention) in China (IM) (NCT05354089)